skip to main content

Bladder Cancer Molecular Subtypes — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardUrological CancersBladder Cancer Molecular SubtypesSCE Medical Oncology

A patient has unresectable metastatic urothelial carcinoma with a susceptible FGFR3 alteration. Disease has progressed after platinum chemotherapy followed by a PD-L1 inhibitor, and performance status remains adequate. Which targeted option matches NICE TA1062?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Erdafitinib after PD-L1 inhibitor progression

Option B is correct: TA1062 recommends erdafitinib after a line containing PD-1 or PD-L1 treatment in susceptible FGFR3-altered unresectable or metastatic urothelial cancer. Option E is not selected by FGFR3. Option D requires a different repair biomarker. Option C targets EGFR, and option A requires HER2-directed context.

Reference: NICE TA1062: erdafitinib for FGFR3-altered urothelial cancer. https://www.nice.org.uk/guidance/ta1062/chapter/1-Recommendation